FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Cannon Louis A		 2. Issuer Name and Ticker or Trading Symbol

Corindus Vascular Robotics, Inc. [ CVRS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

309 WAVERLEY OAKS ROAD, SUITE 105		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/7/2019
(Street)

WALTHAM, MA 02452
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/7/2019    A    1639 (1) A $4.27  303440 (2) D (3)  
Common Stock                 7557436  I  See Footnote (4)
Common Stock                 573798  I  See Footnote (5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The common stock was issued to the reporting person pursuant to the Corindus Vascular Robotics, Inc. ("Corindus") Director Compensation Policy in lieu of the reporting person's quarterly board and board committee retainers of $7,000.
(2)  Includes 27,649 shares of common stock related to RSUs granted as part of the director's 2019 annual equity award. The RSUs provide for vesting in quarterly installments on August 3, 2019, November 3, 2019, February 3, 2020 and May 3, 2020, subject to the reporting person's continuous service with Corindus through each such vesting date.
(3)  175,801 shares are held in Cardiac & Vascular Research Center 401k FBO Louis A. Cannon; the remaining shares are held directly.
(4)  Consists of securities directly owned by BioStar Ventures III, L.P. Dr. Cannon is the founder and Senior Managing Director of BioStar Ventures III, L.P. and, as such, may be deemed to beneficially own the securities held of record by BioStar Ventures III, L.P. for purposes of Rule 16a-1(a). Dr. Cannon disclaims any beneficial ownership of the securities reported, except to the extent of any pecuniary interest therein.
(5)  Consists of securities directly owned by BioStar Ventures III-XP, L.P. Dr. Cannon is the founder and Senior Managing Director of BioStar Ventures III-XP, L.P. and, as such, may be deemed to beneficially own the securities held of record by BioStar Ventures III-XP, L.P. for purposes of Rule 16a-1(a). Dr. Cannon disclaims beneficial ownership of the securities reported except to the extent of any pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Cannon Louis A
309 WAVERLEY OAKS ROAD, SUITE 105
WALTHAM, MA 02452 		X



Signatures
/s/ Louis A. Cannon 10/9/2019
**Signature of Reporting Person Date


Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Corindus Vascular Robotics Charts.
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Corindus Vascular Robotics Charts.

Corindus Vascular Robotics, Inc. News

Real-Time news about Corindus Vascular Robotics Inc (American Stock Exchange): 0 recent articles

More Corindus Vascular Robotics, Inc. News Articles

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.